Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M CLINTON

Showing results (251-260 of 254) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 254 results.
Communications Biology|April 8, 2024
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicinKaruna Mittal, Garrett W Cooper, Benjamin P Lee, et al.
Elife|March 13, 2019
Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibitionAndrew L Hong, Yuen-Yi Tseng, Jeremiah A Wala, et al.
Nature Medicine|June 23, 2022
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancerAlanna J Church, Laura B Corson, Pei-Chi Kao, et al.
Cancer Discovery|February 10, 2021
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP ConsortiumYana Pikman, Sarah K Tasian, Maria Luisa Sulis, et al.
Pageof 26

Showing results (251-260 of 254) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 254 results.
Communications Biology|April 8, 2024
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicinKaruna Mittal, Garrett W Cooper, Benjamin P Lee, et al.
Elife|March 13, 2019
Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibitionAndrew L Hong, Yuen-Yi Tseng, Jeremiah A Wala, et al.
Nature Medicine|June 23, 2022
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancerAlanna J Church, Laura B Corson, Pei-Chi Kao, et al.
Cancer Discovery|February 10, 2021
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP ConsortiumYana Pikman, Sarah K Tasian, Maria Luisa Sulis, et al.
Pageof 26